Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis
Objective Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the...
Gespeichert in:
Veröffentlicht in: | Annals of neurology 2006-07, Vol.60 (1), p.45-55 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 55 |
---|---|
container_issue | 1 |
container_start_page | 45 |
container_title | Annals of neurology |
container_volume | 60 |
creator | Ifergan, Igal Wosik, Karolina Cayrol, Romain Kébir, Hania Auger, Chantale Bernard, Monique Bouthillier, Alain Moumdjian, Robert Duquette, Pierre Prat, Alexandre |
description | Objective
Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the anti‐inflammatory effects of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors within the central nervous system arose from studies demonstrating that statins improve clinical signs in the animal model of MS and reduce the number of gadolinium‐enhancing lesions in MS.
Methods
We sought to describe the impact of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor treatment on the physiology and immunology of human BBB‐derived endothelial cells (ECs).
Results
We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [14C]‐sucrose across human BBB‐ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE‐cadherin, JAM‐1, zonula occluden‐1, and zonula occluden‐2. Simvastatin and lovastatin were equipotent in reducing BBB permeability in vitro, with median effective concentration (EC50) of 9.5 × 10−8 and 1.0 × 10−7M, respectively. We further demonstrate that lovastatin and simvastatin treatment of BBB‐ECs significantly restricts the migration of clinically isolated syndrome–derived and MS‐derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein‐1/CCL2 and interferon‐γ–inducible protein‐10/CXCL10 by BBB‐ECs.
Interpretation
Our data parallel the previously reported magnetic resonance imaging–based radiological findings and suggest an effect of statins that could be beneficial in early MS, restricting the diffusion of molecular tracers and the migration of immune cells across the human BBB. Ann Neurol 2006 |
doi_str_mv | 10.1002/ana.20875 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68707911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68707911</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4575-66f29de7713fc51860d13df18a5df64b7c0e4164cc97cb6ef7f6c700a7270ba73</originalsourceid><addsrcrecordid>eNp1kMFu1DAQhi0EokvhwAsgX0DikNZOHDvhtlqVgliKREF7tCbOGEydZLGdln17THfbnjjNHL7_n9FHyEvOTjhj5SmMcFKyRtWPyILXFS-aUrSPyYJVUhQ1r8QReRbjL8ZYKzl7So64VGVbtnxBbi4TJDdGGrCfDdKf8wAj7fw09UUXwOUdQnAY6BbDgNA579KOwtjnREzBmUQ9zleT2SWkg_sRct00vqNf0eM1jLkyTXSYfXJbjzQaj2GKLj4nTyz4iC8O85h8f3_2bfWhWH85_7hargsjalUXUtqy7VEpXllT80aynle95Q3UvZWiU4ah4FIY0yrTSbTKSqMYA1Uq1oGqjsmbfe82TL_n_LEeXDToPYw4zVHLRjHVcp7Bt3vQ5P9iQKu3wQ0Qdpoz_c-yzpb1reXMvjqUzt2A_QN50JqB1wcAogFvQxbh4gOnWiHK26LTPXfjPO7-f1EvL5Z3p4t9wsWEf-4TEK60VFUmNxfnel1v5OfV5lJ_qv4CTBSlKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68707911</pqid></control><display><type>article</type><title>Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Ifergan, Igal ; Wosik, Karolina ; Cayrol, Romain ; Kébir, Hania ; Auger, Chantale ; Bernard, Monique ; Bouthillier, Alain ; Moumdjian, Robert ; Duquette, Pierre ; Prat, Alexandre</creator><creatorcontrib>Ifergan, Igal ; Wosik, Karolina ; Cayrol, Romain ; Kébir, Hania ; Auger, Chantale ; Bernard, Monique ; Bouthillier, Alain ; Moumdjian, Robert ; Duquette, Pierre ; Prat, Alexandre</creatorcontrib><description>Objective
Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the anti‐inflammatory effects of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors within the central nervous system arose from studies demonstrating that statins improve clinical signs in the animal model of MS and reduce the number of gadolinium‐enhancing lesions in MS.
Methods
We sought to describe the impact of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor treatment on the physiology and immunology of human BBB‐derived endothelial cells (ECs).
Results
We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [14C]‐sucrose across human BBB‐ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE‐cadherin, JAM‐1, zonula occluden‐1, and zonula occluden‐2. Simvastatin and lovastatin were equipotent in reducing BBB permeability in vitro, with median effective concentration (EC50) of 9.5 × 10−8 and 1.0 × 10−7M, respectively. We further demonstrate that lovastatin and simvastatin treatment of BBB‐ECs significantly restricts the migration of clinically isolated syndrome–derived and MS‐derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein‐1/CCL2 and interferon‐γ–inducible protein‐10/CXCL10 by BBB‐ECs.
Interpretation
Our data parallel the previously reported magnetic resonance imaging–based radiological findings and suggest an effect of statins that could be beneficial in early MS, restricting the diffusion of molecular tracers and the migration of immune cells across the human BBB. Ann Neurol 2006</description><identifier>ISSN: 0364-5134</identifier><identifier>EISSN: 1531-8249</identifier><identifier>DOI: 10.1002/ana.20875</identifier><identifier>PMID: 16729291</identifier><identifier>CODEN: ANNED3</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Biological and medical sciences ; Blood-Brain Barrier - drug effects ; Blood-Brain Barrier - immunology ; Capillary Permeability - drug effects ; Capillary Permeability - immunology ; Cell Movement - immunology ; Cells, Cultured ; Chemokine CCL2 - metabolism ; Chemokine CCL2 - secretion ; Chemokine CXCL10 ; Chemokines, CXC - metabolism ; Chemokines, CXC - secretion ; Endothelial Cells - cytology ; Endothelial Cells - immunology ; Endothelial Cells - metabolism ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Immunomodulators ; In Vitro Techniques ; Leukocytes - cytology ; Leukocytes - drug effects ; Leukocytes - secretion ; Lovastatin - pharmacology ; Male ; Medical sciences ; Membrane Proteins - metabolism ; Monocytes - cytology ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - immunology ; Multiple Sclerosis - metabolism ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology ; Occludin ; Pharmacology. Drug treatments ; Phosphoproteins - metabolism ; Protein Prenylation ; Simvastatin - pharmacology ; Tight Junctions - drug effects ; Tight Junctions - metabolism ; Zonula Occludens-1 Protein</subject><ispartof>Annals of neurology, 2006-07, Vol.60 (1), p.45-55</ispartof><rights>Copyright © 2006 American Neurological Association</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4575-66f29de7713fc51860d13df18a5df64b7c0e4164cc97cb6ef7f6c700a7270ba73</citedby><cites>FETCH-LOGICAL-c4575-66f29de7713fc51860d13df18a5df64b7c0e4164cc97cb6ef7f6c700a7270ba73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fana.20875$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fana.20875$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17944275$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16729291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ifergan, Igal</creatorcontrib><creatorcontrib>Wosik, Karolina</creatorcontrib><creatorcontrib>Cayrol, Romain</creatorcontrib><creatorcontrib>Kébir, Hania</creatorcontrib><creatorcontrib>Auger, Chantale</creatorcontrib><creatorcontrib>Bernard, Monique</creatorcontrib><creatorcontrib>Bouthillier, Alain</creatorcontrib><creatorcontrib>Moumdjian, Robert</creatorcontrib><creatorcontrib>Duquette, Pierre</creatorcontrib><creatorcontrib>Prat, Alexandre</creatorcontrib><title>Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis</title><title>Annals of neurology</title><addtitle>Ann Neurol</addtitle><description>Objective
Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the anti‐inflammatory effects of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors within the central nervous system arose from studies demonstrating that statins improve clinical signs in the animal model of MS and reduce the number of gadolinium‐enhancing lesions in MS.
Methods
We sought to describe the impact of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor treatment on the physiology and immunology of human BBB‐derived endothelial cells (ECs).
Results
We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [14C]‐sucrose across human BBB‐ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE‐cadherin, JAM‐1, zonula occluden‐1, and zonula occluden‐2. Simvastatin and lovastatin were equipotent in reducing BBB permeability in vitro, with median effective concentration (EC50) of 9.5 × 10−8 and 1.0 × 10−7M, respectively. We further demonstrate that lovastatin and simvastatin treatment of BBB‐ECs significantly restricts the migration of clinically isolated syndrome–derived and MS‐derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein‐1/CCL2 and interferon‐γ–inducible protein‐10/CXCL10 by BBB‐ECs.
Interpretation
Our data parallel the previously reported magnetic resonance imaging–based radiological findings and suggest an effect of statins that could be beneficial in early MS, restricting the diffusion of molecular tracers and the migration of immune cells across the human BBB. Ann Neurol 2006</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Blood-Brain Barrier - drug effects</subject><subject>Blood-Brain Barrier - immunology</subject><subject>Capillary Permeability - drug effects</subject><subject>Capillary Permeability - immunology</subject><subject>Cell Movement - immunology</subject><subject>Cells, Cultured</subject><subject>Chemokine CCL2 - metabolism</subject><subject>Chemokine CCL2 - secretion</subject><subject>Chemokine CXCL10</subject><subject>Chemokines, CXC - metabolism</subject><subject>Chemokines, CXC - secretion</subject><subject>Endothelial Cells - cytology</subject><subject>Endothelial Cells - immunology</subject><subject>Endothelial Cells - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Immunomodulators</subject><subject>In Vitro Techniques</subject><subject>Leukocytes - cytology</subject><subject>Leukocytes - drug effects</subject><subject>Leukocytes - secretion</subject><subject>Lovastatin - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Proteins - metabolism</subject><subject>Monocytes - cytology</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - immunology</subject><subject>Multiple Sclerosis - metabolism</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><subject>Occludin</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphoproteins - metabolism</subject><subject>Protein Prenylation</subject><subject>Simvastatin - pharmacology</subject><subject>Tight Junctions - drug effects</subject><subject>Tight Junctions - metabolism</subject><subject>Zonula Occludens-1 Protein</subject><issn>0364-5134</issn><issn>1531-8249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMFu1DAQhi0EokvhwAsgX0DikNZOHDvhtlqVgliKREF7tCbOGEydZLGdln17THfbnjjNHL7_n9FHyEvOTjhj5SmMcFKyRtWPyILXFS-aUrSPyYJVUhQ1r8QReRbjL8ZYKzl7So64VGVbtnxBbi4TJDdGGrCfDdKf8wAj7fw09UUXwOUdQnAY6BbDgNA579KOwtjnREzBmUQ9zleT2SWkg_sRct00vqNf0eM1jLkyTXSYfXJbjzQaj2GKLj4nTyz4iC8O85h8f3_2bfWhWH85_7hargsjalUXUtqy7VEpXllT80aynle95Q3UvZWiU4ah4FIY0yrTSbTKSqMYA1Uq1oGqjsmbfe82TL_n_LEeXDToPYw4zVHLRjHVcp7Bt3vQ5P9iQKu3wQ0Qdpoz_c-yzpb1reXMvjqUzt2A_QN50JqB1wcAogFvQxbh4gOnWiHK26LTPXfjPO7-f1EvL5Z3p4t9wsWEf-4TEK60VFUmNxfnel1v5OfV5lJ_qv4CTBSlKA</recordid><startdate>200607</startdate><enddate>200607</enddate><creator>Ifergan, Igal</creator><creator>Wosik, Karolina</creator><creator>Cayrol, Romain</creator><creator>Kébir, Hania</creator><creator>Auger, Chantale</creator><creator>Bernard, Monique</creator><creator>Bouthillier, Alain</creator><creator>Moumdjian, Robert</creator><creator>Duquette, Pierre</creator><creator>Prat, Alexandre</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Willey-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200607</creationdate><title>Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis</title><author>Ifergan, Igal ; Wosik, Karolina ; Cayrol, Romain ; Kébir, Hania ; Auger, Chantale ; Bernard, Monique ; Bouthillier, Alain ; Moumdjian, Robert ; Duquette, Pierre ; Prat, Alexandre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4575-66f29de7713fc51860d13df18a5df64b7c0e4164cc97cb6ef7f6c700a7270ba73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Blood-Brain Barrier - drug effects</topic><topic>Blood-Brain Barrier - immunology</topic><topic>Capillary Permeability - drug effects</topic><topic>Capillary Permeability - immunology</topic><topic>Cell Movement - immunology</topic><topic>Cells, Cultured</topic><topic>Chemokine CCL2 - metabolism</topic><topic>Chemokine CCL2 - secretion</topic><topic>Chemokine CXCL10</topic><topic>Chemokines, CXC - metabolism</topic><topic>Chemokines, CXC - secretion</topic><topic>Endothelial Cells - cytology</topic><topic>Endothelial Cells - immunology</topic><topic>Endothelial Cells - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Immunomodulators</topic><topic>In Vitro Techniques</topic><topic>Leukocytes - cytology</topic><topic>Leukocytes - drug effects</topic><topic>Leukocytes - secretion</topic><topic>Lovastatin - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Proteins - metabolism</topic><topic>Monocytes - cytology</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - immunology</topic><topic>Multiple Sclerosis - metabolism</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><topic>Occludin</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphoproteins - metabolism</topic><topic>Protein Prenylation</topic><topic>Simvastatin - pharmacology</topic><topic>Tight Junctions - drug effects</topic><topic>Tight Junctions - metabolism</topic><topic>Zonula Occludens-1 Protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ifergan, Igal</creatorcontrib><creatorcontrib>Wosik, Karolina</creatorcontrib><creatorcontrib>Cayrol, Romain</creatorcontrib><creatorcontrib>Kébir, Hania</creatorcontrib><creatorcontrib>Auger, Chantale</creatorcontrib><creatorcontrib>Bernard, Monique</creatorcontrib><creatorcontrib>Bouthillier, Alain</creatorcontrib><creatorcontrib>Moumdjian, Robert</creatorcontrib><creatorcontrib>Duquette, Pierre</creatorcontrib><creatorcontrib>Prat, Alexandre</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ifergan, Igal</au><au>Wosik, Karolina</au><au>Cayrol, Romain</au><au>Kébir, Hania</au><au>Auger, Chantale</au><au>Bernard, Monique</au><au>Bouthillier, Alain</au><au>Moumdjian, Robert</au><au>Duquette, Pierre</au><au>Prat, Alexandre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis</atitle><jtitle>Annals of neurology</jtitle><addtitle>Ann Neurol</addtitle><date>2006-07</date><risdate>2006</risdate><volume>60</volume><issue>1</issue><spage>45</spage><epage>55</epage><pages>45-55</pages><issn>0364-5134</issn><eissn>1531-8249</eissn><coden>ANNED3</coden><abstract>Objective
Dysregulation of the blood–brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the anti‐inflammatory effects of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors within the central nervous system arose from studies demonstrating that statins improve clinical signs in the animal model of MS and reduce the number of gadolinium‐enhancing lesions in MS.
Methods
We sought to describe the impact of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor treatment on the physiology and immunology of human BBB‐derived endothelial cells (ECs).
Results
We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [14C]‐sucrose across human BBB‐ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE‐cadherin, JAM‐1, zonula occluden‐1, and zonula occluden‐2. Simvastatin and lovastatin were equipotent in reducing BBB permeability in vitro, with median effective concentration (EC50) of 9.5 × 10−8 and 1.0 × 10−7M, respectively. We further demonstrate that lovastatin and simvastatin treatment of BBB‐ECs significantly restricts the migration of clinically isolated syndrome–derived and MS‐derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein‐1/CCL2 and interferon‐γ–inducible protein‐10/CXCL10 by BBB‐ECs.
Interpretation
Our data parallel the previously reported magnetic resonance imaging–based radiological findings and suggest an effect of statins that could be beneficial in early MS, restricting the diffusion of molecular tracers and the migration of immune cells across the human BBB. Ann Neurol 2006</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16729291</pmid><doi>10.1002/ana.20875</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0364-5134 |
ispartof | Annals of neurology, 2006-07, Vol.60 (1), p.45-55 |
issn | 0364-5134 1531-8249 |
language | eng |
recordid | cdi_proquest_miscellaneous_68707911 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Adult Biological and medical sciences Blood-Brain Barrier - drug effects Blood-Brain Barrier - immunology Capillary Permeability - drug effects Capillary Permeability - immunology Cell Movement - immunology Cells, Cultured Chemokine CCL2 - metabolism Chemokine CCL2 - secretion Chemokine CXCL10 Chemokines, CXC - metabolism Chemokines, CXC - secretion Endothelial Cells - cytology Endothelial Cells - immunology Endothelial Cells - metabolism Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Immunomodulators In Vitro Techniques Leukocytes - cytology Leukocytes - drug effects Leukocytes - secretion Lovastatin - pharmacology Male Medical sciences Membrane Proteins - metabolism Monocytes - cytology Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Multiple Sclerosis - metabolism Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology Occludin Pharmacology. Drug treatments Phosphoproteins - metabolism Protein Prenylation Simvastatin - pharmacology Tight Junctions - drug effects Tight Junctions - metabolism Zonula Occludens-1 Protein |
title | Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A53%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statins%20reduce%20human%20blood-brain%20barrier%20permeability%20and%20restrict%20leukocyte%20migration:%20Relevance%20to%20multiple%20sclerosis&rft.jtitle=Annals%20of%20neurology&rft.au=Ifergan,%20Igal&rft.date=2006-07&rft.volume=60&rft.issue=1&rft.spage=45&rft.epage=55&rft.pages=45-55&rft.issn=0364-5134&rft.eissn=1531-8249&rft.coden=ANNED3&rft_id=info:doi/10.1002/ana.20875&rft_dat=%3Cproquest_cross%3E68707911%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68707911&rft_id=info:pmid/16729291&rfr_iscdi=true |